Bilateral primary breast lymphoma (PBL); case report

Hashemi E: Assistant professor of surgery, Iranian Center for Breast Cancer
Jamali M: professor of pathology, Tehran University of Medical Science
Mehrdad N: Research fellow, Iranian Center for Breast Cancer

Introduction
Extranodal lymphomas account for 10–40% of all malignant Lymphomas [1]. The most common anatomic site of a primary extranodal lymphoma is the gastrointestinal tract (stomach and ileocecal region), but virtually any extranodal location may be a primary site including the skin, CVS, bone, testis, soft tissue, thyroid, etc.

Primary breast Lymphomas (PBL) account for 1.7% to 2.2% of extranodal Lymphomas, 0.04% to 1.1% of breast neoplasms, and 0.38% to 0.7% of non-Hodgkin's Lymphomas [2, 3, 4]. The predominant pathologic type of PBL is diffuse large B-cell Lymphomas, but other types can be found [3, 5, 6].

The median age of patients diagnosed with PNHLB is between 40 and 67 yr, but the range is broad; thus, these tumors can appear in teenagers or patients in their 90’s, the peak age incidence usually is during the sixth decade [7, 15]. All published series reported an overwhelming female predominance [7-9].

The clinical presentation of lymphoma in the breast is similar to other breast malignancy, with a single or multiple painless masses in breast parenchyma. About 13% of patients have bilateral breast involvement. Axillary nodes are involved in 30-40% of cases. Radiographic imaging features of PBL are nonspecific, with the exception that calcifications are rare [10, 11].

In the past, radical mastectomy with postoperative irradiation to the chest and regional nodes was widely used for treatment. Because these tumors respond readily to radiation and to chemotherapy, it seems that these patients could be managing with biopsy or local excision followed by radiation or chemotherapy, usually both.

The role of surgery in PBL should be limited to acquisition of adequate material for diagnosis, typically with a biopsy either from the breast mass or from an involved lymph node. Treatment by mastectomy offers no survival benefit or protection from recurrence [3].

Systemic chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP) is currently the standard of care for patients with diffuse large B-cell, and this regimen should be used in patients with PBL as well [12-14].

We report a patient with PBL and solitary pancreatic mass.

Case Report
A 17-year-old girl was referred to Iranian Center for Breast Cancer surgery clinic because of bilateral painless breast mass in November 2006. Family history was negative for breast cancer. Physical exam of the breasts showed bilateral breast mass with irregular margins. The mean
Bilateral primary breast...

References